Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Related records

Trials (42)

• A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
• A Phase I Study of JSKN021 in Advanced Solid Tumors
• A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
• A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
• A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
• A Study of JSKN027 in Patients With Advanced Solid Tumors
• A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
• A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
• Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
• Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
• Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
• Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
• JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
• JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
• JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
• JSKN022 in Subjects With Advanced Malignant Solid Tumors
• JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
• JSKN033 in Chinese Subjects with Advanced Malignant Tumors
• JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors